Intensity Therapeutics, Inc. (INTS) Key Metrics
INTS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.9M
- Enterprise value
- $3.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.08
INTS key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsINTS returns How much profit the business earns on the capital it uses.
INTS financial health Debt, liquidity and how easily interest is covered.
INTS efficiency & capital use Working capital cycle and where the cash goes.
INTS valuation history
INTS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
INTS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
INTS cash returned to shareholders
INTS price vs earnings per share
INTS key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $13.9M | — | — | — | — | — | — |
| Enterprise value | $2.1M | — | — | — | — | — | — |
| Price / book | 1.2 | — | — | — | — | — | — |
| Earnings yield | −83.5% | — | — | — | — | — | — |
| Free cash flow yield | −66.4% | — | — | — | — | — | — |
| Share price at fiscal year-end | $10.25 | $44.00 | $214.25 | — | — | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$8.56 | — | — | — | — | — | — |
| Operating cash flow per share | −$6.81 | — | — | — | — | — | — |
| Free cash flow per share | −$6.81 | — | — | — | — | — | — |
| Cash per share | $8.79 | — | — | — | — | — | — |
| Book value per share | $8.76 | — | — | — | — | — | — |
| Tangible book value per share | $8.76 | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — |
| Debt per share | $0.08 | — | — | — | — | — | — |
| Shares outstanding | 1.4M | — | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −156.9% | −202.3% | — | — | — | — | −67.9% |
| Return on assets (ROA) | −122.9% | −147.4% | −110.6% | −217.5% | −102.7% | −62.2% | −58.1% |
| Return on tangible assets | −82.3% | −340.1% | −60.9% | −431.5% | −151.3% | −58.7% | −58.1% |
| Financial health | |||||||
| Total debt | $110,000 | $138,000 | $158,000 | $4.5M | $2.3M | $497,481 | $260,270 |
| Cash & short-term investments | $11.9M | $2.6M | $14.8M | $1.3M | $4.5M | $9.3M | $8.4M |
| Net debt | −$11.8M | −$2.5M | −$14.6M | $3.2M | −$2.2M | −$8.8M | −$8.1M |
| Debt / equity | 0.01 | 0.05 | 0.01 | — | — | — | 0.03 |
| Debt / assets | 0.01 | 0.03 | 0.01 | 2.56 | 0.45 | 0.05 | 0.03 |
| Current ratio | 5.92 | 1.92 | 3.91 | 0.21 | 1.27 | 7.04 | 7.67 |
| Quick ratio | 5.92 | 1.92 | 3.91 | 0.21 | 1.25 | 6.88 | 7.48 |
| Interest coverage | — | — | -27.3 | -92.3 | -477.9 | — | — |
| Working capital | $10.6M | $1.6M | $11.5M | −$5.4M | $1.0M | $8.1M | $7.5M |
| Invested capital | $65,000 | $466,000 | −$1.5M | −$11.9M | −$10.9M | −$10.4M | −$434,348 |
| Tangible asset value | $11.9M | $2.9M | $13.2M | −$15.1M | −$8.7M | −$1.6M | $7.7M |
| Net current asset value | $10.5M | $1.5M | $11.3M | −$15.4M | −$9.2M | −$2.2M | $7.3M |
| Graham net-net per share | $7.15 | — | — | — | — | — | — |
| Capital allocation | |||||||
| Dividends paid | — | — | $1.3M | — | — | — | — |
| Share buybacks (net) | — | — | $0 | — | — | — | — |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | |||||||
| Days of inventory on hand | — | — | — | 101.7 | — | — | — |
| Days payables outstanding | 12,648.7 | 31,149.1 | 4,532.7 | 790.5 | — | — | — |
| Receivables turnover | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.03 | 0.01 | 0.08 | 0.46 | — | — | — |
| Inventory turnover | — | — | — | 3.59 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $56,783 | $49,892 | $41,078 | $33,634 |
| Average payables | $901,000 | $2.1M | $1.8M | $387,754 | $197,608 | $308,335 | $393,963 |
| Average inventory | — | — | — | $49,902 | $143,809 | $211,321 | $205,468 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from INTS's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
INTS valuation and financial ratios
Intensity Therapeutics earned a return on equity of −156.9% in fiscal 2025. It ended the year with $0.1 million of debt and $11.9 million in cash and short-term investments, a net cash position of $11.8 million.
See the INTS income statement, the INTS chart for price history, or the INTS stock overview for the latest quote and news.
INTS key metrics FAQ
What is Intensity Therapeutics's return on equity?
Intensity Therapeutics's return on equity (ROE) was −156.9% in fiscal 2025: net income of -$11.6 million on average shareholders' equity of $7.4 million.
How much debt does Intensity Therapeutics have?
Intensity Therapeutics had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Intensity Therapeutics's free cash flow yield?
Intensity Therapeutics generated -$9.2 million of free cash flow in fiscal 2025, a free cash flow yield of −66.4% on its market value at year-end ($13.9 million).
What is Intensity Therapeutics's current ratio?
Intensity Therapeutics's current ratio was 5.92 at the end of fiscal 2025: current assets were 5.92 times current liabilities.